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DrGordon Cohen (Seattle, Wash). Because both the PTFE and
the BPF are commercially available, many surgeons have experi-
enced using one or the other or maybe even both, and not surpris-
ingly have an opinion as to why one is better than another.
However, I have yet to hear of this novel approach of anyone using
them both together. As is common in our specialty, we often just
start doing things because we think they are better, but you de-
signed a straightforward and practical study to try and actually an-
swer this question.
I have a few questions for you.
1. Out of curiosity, how do you blind the evaluator to the pres-
ence or absence or PTFE?
2. Is 4 weeks a long enough period for significant adhesions to
form? Is there some relationship between the different ma-
terials and time, that is, would it not have been better to eval-
uate the adhesions at different time points (eg, 1, 3, and 6
months) to really understand the differences?
3. You must have tried this combination in patients. What has
been your experience in actual clinical practice?
4. Finally, just an opinion, do you think that some sort of PTFE
and BPF combination should be a standard of care for pa-
tients who will certainly undergo repeat cardiac surgery?
Because it decreases the risk associated with reoperation
and potentially decreases time, which we could speculate
translates to a reduction in costs.
Dr Kaushal. The first question relates to the blinded observer.
I might have mentioned that in the text, but I have changed that
subsequently because of course you cannot have a blinded ob-
server to PTFE. The observer was actually independent and not
aware of each treatment group, so that is why we used that as an
observer. It was not blinded.
The second question asks why did I look at 4 weeks and was
there a long-lasting effect of preventing adhesions beyond the 1
month, to 3 or 6 months. The reason why I chose 4 weeks is thatThe Journal of Thoracic and Cawe have additional data that we did not present where we have
looked at the adhesion formation along an interval course, span-
ning 1, 3, and 6 months, and what we noticed was that there was
no difference of adhesion formation in that time period, so that
is why we subsequently reduced our evaluation to just 1 month.
Your third question involves the clinical utility of this and have
we used that in our patients. We have not used that currently. Our
plans are to start a clinical trial this fall. We think that using this
combination will prevent adhesion formation. I think the best
way to analyze something before it is the standard of care, which
deals with your fourth question, is that we have to rigorously study
this and make sure that it is safe and effective.
Speaker. If the physical barrier and BPF work sowell, have you
ever tried using a sandwich with BPF on one side and the other side
underneath the sternum so it prevents the adhesions and the PTFE
is in the middle?
Dr Kaushal. That is a very good thought, and in fact our next
set of experiments are exactly that. As I mentioned in our PTFE
group where we used the combination, there was adhesion forma-
tion between the sternum and the PTFE, so our thoughts were, as
you just mentioned, that maybewe can use a triple sandwich where
we use BPF, PTFE, and BPF to prevent adhesion formation
throughout that area.
Dr Pirooz Eghtesady (Cincinnati, Ohio). Two questions. What
is the cost for these 2 things, and, at least from my perspective, the
PTFE does a nice job ensuring safety during reentry, but a big pain
is when you have to dissect the right atrium off the pericardium,
dissect between the aorta and the pulmonary more down below.
Does this stuff sort of trickle down from the surface and prevent
those adhesions?
I do not know if one could do this. I think a corollary would be if
you want to make it clinical conversion either looking at the time it
takes to have a certain exposure if you did an animal study or injury
during that process as you were trying to set things up.
Dr Kaushal. I do not have the exact price for the BPF, but I can
get that for you if you require it.
Your second question deals with the healing properties of this
and whether you can apply it to different areas, especially the right
atrium. The healing quality of this is actually very good. The com-
pliance of this film is good in the sense that once you soak it for 5
minutes in saline it is pliable, and you can actually cut it to the
shape or size that you require and apply it to the areas you need,
so if you wanted to have more on the right atrium you can actually
do that. I think that is easy. We did not do that in this study.
The timing was actually looked at in the original study per-
formed with the infant surgeries in those patients, and there was
a decrease in time to perform the dissection of adhesion formation.
So that has been looked at in the clinical trial, but it is a good point.
We will look at that in the next trial we perform. I think as we have
gained experience with re-do sternotomies, our mortality rate has
definitely decreased, and there have been 2 different reports stating
the ease of a re-do, is that a risk factor for mortality, and it is not
really a risk factor anymore for mortality, but I think what will
come out of that is why we are pursuing this. This will be another
adjunct in preventing injuries that do not result in mortality but in
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